Timothy Illidge, MBBS, PhD, MRCP, FRCR, FRCPath
Timothy Illidge is Professor of Targeted Therapy and Oncology at the School of Cancer and Imaging Sciences, Manchester University, UK, a post he has held since 2004. He is also group leader for the Cancer Research UK (CRUK) Targeted Therapy Group based at the Paterson Institute, and leads the clinical nuclear medicine therapy group at the Christie Hospital, both in Manchester. After completing his undergraduate degree in biochemistry at London University he received his medical degree from Guy's Hospital Medical School, London, and was subsequently awarded a PhD from the University of Southampton, UK, for his work in the field of targeted radiation and immunotherapy applied to lymphoma. He then completed research fellowships as a CRUK senior clinical research fellow and was appointed Senior Lecturer and Honorary Consultant in Oncology at Southampton University Hospitals NHS Trust in 1999.
Professor Illidge was awarded a US Senior Fulbright fellowship and a Winston Churchill Fellowship, which enabled him to work as part of the lymphoma team at Stanford University, California, in 1998. He moved his research group to Manchester University, based on the Christie Hospital site, in 2004. His clinical interest is in lymphoma, a field in which he has led many early and late phase clinical trials; he is recognized as an international expert in antibodies and radioimmunotherapy applied to lymphoma.
Professor Illidge has published extensively, with more than 100 publications in journals including the British Journal of Cancer, the Journal of Clinical Oncology, Leukemia and Lymphoma, and the Journal of Hematology & Oncology. He serves on the central steering group of the National Cancer Research lymphoma group and has represented the UK at international workshops in lymphoma.